Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sage Therapeutic Com
(NQ:
SAGE
)
13.04
+0.46 (+3.70%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Sage Therapeutic Com
< Previous
1
2
3
4
5
6
Next >
In-Depth Examination Of 9 Analyst Recommendations For Sage Therapeutics
Today 8:00 EDT
Via
Benzinga
Crude Oil Dips 3%; U.S. Bancorp Profit Tops Views
April 17, 2024
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Wednesday. The Dow traded up 0.04% to 37,813.77 while the NASDAQ fell 0.78% to 15,742.21....
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
April 17, 2024
Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings.
Via
Benzinga
Demystifying Sage Therapeutics: Insights From 5 Analyst Reviews
March 26, 2024
Via
Benzinga
Peeling Back The Layers: Exploring Sage Therapeutics Through Analyst Insights
February 28, 2024
Via
Benzinga
Earnings Scheduled For February 14, 2024
February 14, 2024
Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is projected to report quarterly earnings at $1.65 per share on revenue of $24.62 billion.
Via
Benzinga
Nasdaq Down Over 1%; Sage Therapeutics Shares Plunge
April 17, 2024
U.S. stocks traded lower midway through trading, with the Dow Jones index falling around 100 points on Wednesday. The Dow traded down 0.32% to 37,678.27 while the NASDAQ fell 1.16% to 15,681.95. The...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Neurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson's Data
April 17, 2024
Sage Therapeutics' Phase 2 study on dalzanemdor (SAGE-718) for mild cognitive impairment in Parkinson's Disease. Learn about topline results, safety, and future milestones in 2024.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
April 17, 2024
Via
Benzinga
Sage Stock Collapses To Record Low After Parkinson's Drug Misses Its Mark
April 17, 2024
Safe Therapeutics emphasized it's still testing the same drug in patients with Alzheimer's and Huntington's diseases.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
April 17, 2024
Via
Benzinga
The Latest Analyst Ratings for Sage Therapeutics
December 12, 2023
Via
Benzinga
Analyst Ratings for Sage Therapeutics
November 08, 2023
Via
Benzinga
Why Sage Therapeutics Stock Sank Today
November 07, 2023
A secondary stock sale and underwhelming quarterly results sent investors to the off-ramp.
Via
The Motley Fool
J B Hunt Transport Reports Downbeat Earnings, Joins ASML And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
April 17, 2024
U.S. stock futures were higher this morning, with the Dow futures gaining over 100 points on Wednesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
These Analysts Boost Their Forecasts On Sage Therapeutics Following Q4 Results
February 15, 2024
Sage Therapeutics, Inc. (NASDAQ: SAGE) reported better-than-expected fourth-quarter revenue results on Wednesday.
Via
Benzinga
Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
November 07, 2023
Gainers PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry.
Via
Benzinga
The Latest Analyst Ratings for Sage Therapeutics
October 13, 2023
Via
Benzinga
Where Sage Therapeutics Stands With Analysts
September 07, 2023
Via
Benzinga
Earnings Scheduled For November 7, 2023
November 07, 2023
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.
Via
Benzinga
Is Sage Therapeutics a Contrarian Buy?
August 08, 2023
A regulatory setback weighed heavily on the drugmaker's shares Monday.
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
September 08, 2023
Via
Benzinga
3 Healthcare Stocks to Sell in September Before They Crash & Burn
September 06, 2023
The prognosis for these healthcare stocks isn't optimistic so plan to sell them this month before they get worse.
Via
InvestorPlace
Sage Therapeutics Cuts Workforce By 40% Following Rejection In Depression Treatment
August 31, 2023
The company is now focusing on its launch in postpartum depression.
Via
Investor's Business Daily
3 Very Oversold Pharma Stocks to Buy Right Now
August 24, 2023
Oversold pharma stocks have great total return potential. In this article, we list some of the best to buy.
Via
InvestorPlace
Is Sage Therapeutics Stock in Trouble After Dropping 50% in a Month?
August 24, 2023
The pharmaceutical company's growth prospects have taken a big hit.
Via
The Motley Fool
Why Shares of Sage Therapeutics Slumped This Week
August 11, 2023
The company got bad news from the FDA and saw increased losses.
Via
The Motley Fool
Exposures
Product Safety
Consolidated Water, Spectrum Brands, Arco Platform, Semler Scientific And Other Big Stocks Moving Higher On Friday
August 11, 2023
U.S. stocks traded mixed, with the Dow Jones gaining around 80 points on Friday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
2 Beaten-Down Stocks That Still Aren't Worth Buying
August 11, 2023
These companies aren't bargains at all.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2023
August 08, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.